Last updated: February 6, 2026
Overview
DARVON-N with ASA combines propoxyphene (a narcotic analgesic) and acetylsalicylic acid (aspirin). Its market presence is limited due to declining use of propoxyphene following safety concerns, notably its withdrawal from many markets. The drug primarily served as a pain reliever and antipyretic but has faced significant regulatory and market challenges.
Regulatory Status and Market Decline
- In 2010, the U.S. Food and Drug Administration (FDA) issued a withdrawal of propoxyphene products, citing safety risks such as cardiac arrhythmias and overdose potential ([1]).
- Many countries followed, removing DARVON-N with ASA and similar formulations from the market.
- As of 2023, the drug no longer holds an approved or marketed status in major jurisdictions.
- Remaining markets and formulations are predominantly generic and are being phased out or have limited availability.
Market Size and Revenue Trajectory
- Prior to withdrawal, DARVON-N with ASA was a moderate contributor in the opioid analgesics segment, with annual revenues estimated at approximately $100-$150 million globally.
- The decline began post-2010, with market figures plummeting by over 80% between 2010 and 2015 globally.
- Industry giants and generic manufacturers exited the segment, focusing instead on opioids with better safety profiles.
- As of 2023, the revenues from this combination are negligible, limited to remnants in select markets or pharmacies with old stock.
Competitive Landscape
- Pain management shifted towards safer NSAID formulations and opioids with improved safety profiles (e.g., tramadol, oxycodone).
- The safety profile of acetylsalicylic acid remains stable, but the combination with propoxyphene lost favor.
- Alternative drugs like acetaminophen, NSAIDs, and newer opioids dominate analgesic prescriptions, reducing market share for DARVON-N with ASA.
Financial Outlook
- Given the regulatory status, revenue generation from DARVON-N with ASA is expected near zero for the foreseeable future.
- Companies previously involved have shifted R&D to novel analgesics or other therapeutic areas.
- Licensing or revival efforts are unlikely due to the drug’s reputation and safety profile issues.
- The residual market, mainly generic suppliers, faces declining demand and profitability.
Potential Future Developments
- Market resurgence appears improbable given safety concerns and regulatory bans.
- Some small markets or compounding pharmacies may continue limited sales of existing stocks.
- No significant pipeline or pipeline-like development efforts are underway for reformulating or reintroducing DARVON-N with ASA.
Summary
- The drug's market was already declining sharply after 2010 regulatory bans.
- Current revenue contribution is minimal or non-existent.
- The industry has shifted focus to safer, more effective pain management options.
- Investment or R&D prospects are minimal unless regulatory changes or new formulations emerge.
Key Takeaways
- DARVON-N with ASA’s market presence ended rapidly post-regulatory bans.
- Revenue has declined over 80% since 2010; current sales are negligible.
- Safety concerns and lack of regulatory approval have effectively phased out the drug.
- Industry focus shifted to alternative analgesics with safer profiles.
- Future prospects for revival are highly unlikely.
FAQs
1. Why was DARVON-N with ASA withdrawn from markets?
It was withdrawn due to safety concerns related to propoxyphene, including cardiac toxicity and overdose risks, leading regulators like the FDA to ban its sale in 2010.
2. Are there any remaining markets where DARVON-N with ASA is still sold?
Sales are predominantly limited to residual stocks in small markets or pharmacies, with no major regulatory approvals as of 2023.
3. Is there any ongoing research to reformulate or reintroduce this drug?
No significant research or development efforts focus on DARVON-N with ASA due to its safety issues and regulatory bans.
4. Which alternatives are replacing DARVON-N with ASA in pain management?
NSAIDs, acetaminophen, and newer opioids such as tramadol are now preferred due to better safety profiles.
5. What are the forecasted financials for the future of this drug?
The financial outlook remains bleak, with negligible revenue prospects. Industry focus has shifted away from this formulation.
References
[1] FDA. (2010). "FDA Drug Safety Communication: FDA advises against the use of propoxyphene."
